FEATURES OF THE EXPRESSION OF MATRICELLULAR GENES (OSTEOPONTIN AND OSTEONECTIN) IN BENIGN AND MALIGNANT TUMORS OF THE PROSTATIC GLAND
DOI:
https://doi.org/10.15407/oncology.2023.01.047Keywords:
prostate cancer, benign prostatic hyperplasia, osteopontin, osteonectin, SPP1, SPARCAbstract
Summary. Prostate cancer (PCa) is one of the most common oncological diseases in men both in Ukraine and in the world, which determines the need to search for new diagnostic and prognostic markers. According to the data of modern literature, a characteristic feature of malignant growth and progression is the remodeling of the extracellular matrix on the background of an increase in the expression of matricellular proteins (MCP). Aim: to conduct a comparative study of the expression of matricellular genes at the level of mRNA (SPP1 and SPARC) and protein (OPN and ON) in the tissue of benign and malignant tumors of the prostate gland. Objects ОРИГІНАЛЬНІ ДОСЛІДЖЕННЯ 5 4 ОНКОЛОГІЯ • Т. 25 • № 1 • 2023 Одержано: 25.04.2023 and methods: the work is based on the analysis of the results of examination and treatment of 50 patients with stage II–III prostate cancer and 20 patients with benign prostatic hyperplasia (BPH), who were treated during 2015–2021 at the National Cancer Institute of the Ministry of Health of Ukraine. The study of the expression of matricellular genes at the level of mRNA and protein in the PCa and BPH tissues was carried out using the methods of real-time polymerase chain reaction and immunohistochemistry, respectively. The bioinformatical study of SPP1 and SPARC expression in the tissue of BPH and PCa was carried out using the сamсАРP resource on the Cambridge Dataset (2015). The analysis of the recurrence-free survival rates of patients with PCa depending on the expression of SPP1 and SPARC was carried out using the PROGgeneV2 (GSE40272 Dataset). Statistical analysis was performed using GraphPad Prism v. 8.00. Results: the analysis of the results of the immunohistochemical study of the MCP established that the PCa tissue is characterized by a high level of OPN and ON. It has been demonstrated that the level of ON expression in the PCa tissue is 2.5 (p < 0.05) times higher compared to BPH tissue. It was found that the level of SPP1 and SPARC in the PCa tissue was 3.9 (p < 0.05) and 28.9 (p < 0.05) times higher compared to the corresponding expression indicators of the studied genes in the tissue of the BPH. It is shown that the rate of recurrence-free 5-year survival decreased by 20.0% (p < 0.05) in patients with PCa with a high level of SPARC mRNA in the tumor tissue. Conclusions: the obtained results indicate the need for further study of the role of MCP genes in the mechanisms of the development of PCa with the aim of using these indicators as markers for the differential diagnosis of the tumor process.
References
Gordon-Weeks A, Yuzhalin AE. Cancer extracellular matrix proteins regulate tumour immunity. Cancers 2020; 12 (11): 3331. doi: 10.3390/cancers12113331
Gopinath P, Natarajan A, Sathyanarayanan A, et al. The multifaceted role of Matricellular Proteins in health and cancer, as biomarkers and therapeutic targets. Gene 2022; 815: 146137. doi: 10.1016/j.gene.2021.146137
Chiodoni C, Colombo MP, Sangaletti S. Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis. Cancer Metastasis Rev 2010; 29: 295–307. doi: 10.1007/s10555-010-9221-8
Gerarduzzi C, Hartmann U, Leask A, et al. The matrix revolution: matricellular proteins and restructuring of the cancer microenvironment. Cancer Res 2020; 80 (13): 2705–17. doi: 10.1158/0008-5472.CAN-18-2098
Thakur R, Mishra DP. Matrix reloaded: CCN, tenascin and SIBLING group of matricellular proteins in orchestrating cancer hallmark capabilities. Pharmacol Ther 2016; 168: 61–74. doi: 10.1016/j.pharmthera.2016.09.002
Sodek J, Zhu B, Huynh MH, et al. Novel functions of the matricellular proteins osteopontin and osteonectin/SPARC. Connect Tissue Res 2002; 43 (2–3): 308–19. doi: 10.1080/03008200290001050
Viloria K, Hill NJ. Embracing the complexity of matricellular proteins: the functional and clinical significance of splice variation. Biomol Concepts 2016; 7 (2): 117–32. doi: 10.1515/bmc-2016-0004
Wu T, Ouyang G. Matricellular proteins: multifaceted extracellular regulators in tumor dormancy. Protein Cell 2014; 5 (4): 249–52. doi: 10.1007/s13238-014-0023-6
Desai B, Rogers MJ, Chellaiah MA. Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells. Mol Cancer 2007; 6: 1–16. doi: 10.1186/1476-4598-6-18
Al-Wadi AH, Al-A’Araji SB, Ali SJ, et al. Evaluation of serum osteopontin and its relation with other biomarkers of prostate cancer in Iraqi patients. AIP Conference Proceedings 2022; 2450 (1): 020015. doi: 10.1063/5.0095584
Moorman HR, Poschel D, Klement JD, et al. Osteopontin: a key regulator of tumor progression and immunomodulation. Cancers 2020; 12 (11): 3379. doi: 10.3390/cancers12113379
Shevde LA, Samant RS. Role of osteopontin in the pathophysiology of cancer. Matrix Biol 2014; 37: 131–41. doi: 10.1016/j.matbio.2014.03.001
Trotter TN, Yang Y. Matricellular proteins as regulators of cancer metastasis to bone. Matrix Biol 2016; 52: 301–14. doi: 10.1016/j.matbio.2016.01.006
Mateo F, Meca-Cortés Ó, Celià-Terrassa T, et al. SPARC mediates metastatic cooperation between CSC and non-CSC prostate cancer cell subpopulations. Mol Cancer 2014; 13: 1–17. doi: 10.1186/1476-4598-13-237
Jacob K, Webber M, Benayahu D, et al. Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. Cancer Res 1999; 59 (17): 4453–7. PMID: 10485497
Yu A, Guo K, Qin Q, et al. Clinicopathological and prognostic significance of osteopontin expression in patients with prostate cancer: a systematic review and meta-analysis. Biosci Rep 2021; 41 (8): BSR20203531. doi: 10.1042/BSR20203531
Sharma S, Xing F, Liu Y, et al. Secreted protein acidic and rich in cysteine (SPARC) mediates metastatic dormancy of prostate cancer in bone. J Biol Chem 2016; 291 (37), 19351–63. doi: 10.1074/jbc.M116.737379
Said N, Frierson HF, Chernauskas D, et al. The role of SPARC in the TRAMP model of prostate carcinogenesis and progression. Oncogene 2009; 28 (39): 3487–98. doi: 10.1038/onc.2009.205
Sharma S, Xing F, Liu Y, et al. SPARC in tumor microenvironment induces dormancy of prostate cancer in bone. Cancer Res 2015; 75: 3206. doi: 10.1158/1538-7445.AM2015-3206
Nakamura KDM, Tilli TM, Wanderley JL, et al. Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells. Tumor Biol 2016; 37: 2655–63. doi: 10.1007/s13277-015-4095-6
Popovics P, Awadallah WN, Kohrt SE, et al. Prostatic osteopontin expression is associated with symptomatic benign prostatic hyperplasia. The Prostate 2020; 80 (10): 731–41. doi: 10.1002/pros.23986
Zhang JD, Ruschhaupt M, Biczok R. 2013. ddCt method for qRT–PCR data analysis. https://citeseerx.ist.psu.edu/pdf/63727bfe6cc3467c2a02e0816e6451ef242b481b
McClelland RA, Wilson D, Leake R, et al. A multicentre study into the reliability of steroid receptor immunocytochemical assay quantification. British Quality Control Group. Eur J Cancer 1991; 27 (6): 711–5. doi: 10.1016/0277-5379(91)90171-9
Thalmann GN, Sikes RA, Devoll RE, et al. Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 1999, 5 (8): 2271–77. PMID: 10473115
Tilli TM, Thuler LC, Matos AR, et al. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia. Exp Mol Pathol 2012; 92 (1): 13–9. doi: 10.1016/j.yexmp.2011.09.014;
Forootan SS, Foster CS, Aachi VR, et al. Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer 2006; 118 (9): 2255–61. doi: 10.1002/ijc.21619
Thomas S, Waterman P, Chen S, et al. Development of secreted protein and acidic and rich in cysteine (SPARC) targeted nanoparticles for the prognostic molecular imaging of metastatic prostate cancer. J Nanomed Nanotechnol 2011; 2 (112): 2157-7439-2-112. doi: 10.4172/2157-7439.1000112
Danasekaran SM, Barrette TR, Ghosh D. Delineation of prognostic biomarkers in prostate cancer metastasis. Nature 2001; 412 (6849): 822–6. doi: 10.1038/35090585
